Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Revenue increased to $42.9 million in Q4 2023, an 18.7% rise from the previous year.
- Full-year revenue reached $159.0 million, a 14.7% increase from 2022.
- Net loss decreased to $3.9 million in Q4 2023 compared to $5.4 million in Q4 2022.
- Adjusted net loss was $2.6 million in Q4 2023, an improvement from $1.1 million in Q4 2022.
- Gross margin was 78.7% in Q4 2023, down from 83.0% in Q4 2022.
- Axogen plans to launch Avive+ Soft Tissue Matrix in Q2 2024 to strengthen its nerve repair product portfolio.
- The company anticipates revenue between $177 million to $181 million for 2024, with a gross margin of 76% to 79%.
- Axogen completed a productive Pre-BLA meeting with the FDA, aligning on a submission process and timetable for potential approval in mid-2025.
- The company surpassed 100,000 Avance nerve graft implants since 2007 and launched new products like Axoguard HA+ Nerve Protector and Resensation® for breast reconstruction.
- Axogen expects continued growth by expanding its clinical evidence and product offerings in the nerve repair market.
- Gross margin decreased to 78.7% in Q4 2023 from 83.0% in Q4 2022.
- Net loss was $3.9 million in Q4 2023, indicating a financial loss for the quarter.
- Adjusted EBITDA was $0.6 million in Q4 2023, showing a slight improvement from a loss of $0.7 million in Q4 2022.
Insights
The reported revenue growth of 18.7% in Q4 and 14.7% for the full year by Axogen is a strong indicator of the company's upward trajectory in the peripheral nerve repair market. The distinction between emergent trauma and scheduled non-trauma procedures, with the latter growing over 25%, suggests a diversification of revenue streams. However, the decrease in gross margin from 83.0% to 78.7% in Q4 could raise concerns about cost management and pricing strategies. The net loss reduction year-over-year indicates improving operational efficiency, but the fact that the company is still not profitable could be a point of caution for investors.
Adjusted EBITDA turning positive in Q4 is a promising sign of financial health, but the full-year adjusted EBITDA loss, although improved, shows there is still work to be done. The cash balance dip from Q3 to Q4 of 2023 needs to be monitored as it could impact the company's ability to fund operations and growth initiatives. The guidance for 2024, with an expected revenue increase of 11% to 14%, sets a conservative growth target that may reflect market conditions and internal expectations for product adoption.
The completion of a productive Pre-BLA meeting with the FDA and the alignment on a rolling submission process for Axogen's products is a pivotal step for the company. The potential approval in mid-2025 could significantly enhance the company's product portfolio. The operational highlight of processing tissue in a new biologics facility suggests an investment in infrastructure to support long-term growth. Additionally, reaching the milestone of 100,000 Avance nerve graft implants since its launch demonstrates the clinical acceptance and utility of the product in the market.
The expansion into the nerve protection market and the national launch of Axoguard HA+ Nerve Protector™, coupled with the upcoming launch of Avive+ Soft Tissue Matrix™, indicates strategic moves to capture more market share. The launch of Resensation® targets an additional segment of the breast reconstruction market, potentially increasing revenue. The accumulation of 245 peer-reviewed clinical publications is a testament to the company's commitment to evidence-based medicine, which can strengthen its credibility and adoption rate among healthcare professionals.
The growth in Core Accounts by 13.3% and the maintenance of a stable sales force indicate effective market penetration strategies. However, while the company is expanding its product line and clinical evidence, the competitive landscape in the peripheral nerve repair market must be considered, including emerging technologies and potential shifts in healthcare policies. The company's focus on leveraging clinical evidence and expanding use cases is a sound strategy for growth, but it must be agile in responding to market trends and payer dynamics.
The anticipated gross margin range for the full year of 76% to 79% is slightly below the previous year's margin, which might be a result of increased competition or investment in growth initiatives. Axogen's guidance for 2024 indicates cautious optimism and its ability to meet these projections will depend on successful product launches and continued market adoption.
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
Fourth Quarter 2023 Financial Results and Business Highlights
- Fourth quarter revenue was
$42.9 million , an18.7% increase compared to the fourth quarter of 2022. - The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022.
- The Company estimates that revenues from scheduled non-trauma procedures represented approximately half of total revenues during the fourth quarter and grew more than
25% versus the fourth quarter of 2022. - Gross margin was
78.7% for the fourth quarter compared to83.0% in the fourth quarter of 2022. - Net loss for the quarter was
$3.9 million , or$0.09 per share, compared to net loss of$5.4 million , or$0.13 per share in the fourth quarter of 2022. - Adjusted net loss for the quarter was
$2.6 million , or$0.06 per share, compared to adjusted net loss of$1.1 million , or$0.03 per share in the fourth quarter of 2022. - Adjusted EBITDA was
$0.6 million for the quarter, compared to an adjusted EBITDA loss of$0.7 million in the fourth quarter of 2022. - The balance of all cash, cash equivalents, and investments on December 31, 2023 was
$37.0 million , as compared to a balance of$38.6 million on September 30, 2023.
“We are pleased with our solid performance in the fourth quarter, and we are encouraged by the continued momentum we’ve seen in this first quarter,” commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “Looking ahead, we remain focused on further penetrating core accounts by leveraging our growing body of clinical evidence and expanding use cases with our innovative new products and applications. Additionally, we are excited to expand our leadership position in nerve repair with the 2024 Q2 launch of Avive+ Sofit Tissue Matrix, supporting our mission of restoring nerve function and quality of life to patients with peripheral nerve injuries.”
Full-Year Financial Results and Business Highlights
- Full-year 2023 revenue was
$159.0 million , a14.7% increase compared to 2022 revenue of$138.6 million . - Revenue from Core Accounts represents approximately
65% of total revenue. - Gross margin was
80.4% for the full-year, compared to82.6% in 2022. - Net loss for the year was
$21.7 million , or$0.51 per share, compared to net loss of$28.9 million , or$0.69 per share in 2022. - Adjusted net loss was
$7.3 million for the full-year, or$0.17 per share, compared to 12.6 million for the full-year, or$0.30 per share in 2022. - Adjusted EBITDA loss was
$1.1 million for the full-year, compared to an adjusted EBITDA loss of$9.3 million for 2022. - Core Accounts totaled 376, a
13.3% growth over the prior year level of 332. - Ended the fourth quarter with 116 direct sales representatives compared to 116 at the end of the third quarter and 115 on December 31, 2022.
Summary of Operational and Business Highlights
- We recently completed a productive Pre-BLA meeting with FDA. We have aligned with FDA on a rolling submission process and the content of the modules for submission. We anticipate the filing to be completed in the third quarter of 2024. Subject to ongoing engagement with FDA, we currently believe the submission timetable will allow for a potential approval in mid-2025.
- In August 2023, we began processing tissue in the new, state-of-the-art biologics processing facility, which provides for up to three times the previous capacity and was designed for long-term growth and expansion.
- During 2023, we surpassed 100,000 Avance nerve graft implants since launch in 2007.
- We are continuing to expand our offering in the nerve protection market with the national launch of Axoguard HA+ Nerve Protector™ in 2023 and expect to launch Avive+ Soft Tissue Matrix™ in the second quarter of 2024.
- We launched Resensation® for implant-based reconstruction allowing us to access an additional 10
-15% of the overall breast reconstruction market. As part of this launch, we have established a comprehensive training program to support the adoption of this innovative approach to bring sensation to more patients undergoing mastectomy. - We ended the year with 245 peer-reviewed clinical publications featuring Axogen’s nerve repair product portfolio.
2024 Financial Guidance
We expect revenue to be in the range of
Conference Call
The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the Company's website at www.axogeninc.com under Investors.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that are initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance® nerve graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
For more information, visit www.axogeninc.com.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include the Company’s estimates regarding the revenues from scheduled non-trauma procedures and emergent trauma procedures as a portion of the total revenues, Ms. Zaderej’s statements on the Company’s future focus, the Company’s portfolio of clinical data supports the products’ efficacy, cost and time savings, the anticipated timing of the full BLA submission and our expectations that the BLA will be approved in mid-2025, the expected timing of the launch of Avive+ Soft Tissue Matrix, our expectations regarding our ability to access an additional 10
About Non-GAAP Financial Measures
To supplement our consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense and litigation and related expenses. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share - basic and diluted which excludes non-cash stock compensation expense and litigation and related expenses from Net Loss and Net Loss Per Common Share - basic and diluted, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.
We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.
Contact:
Axogen, Inc.
Harold D. Tamayo, Vice President of Finance and Investor Relations
htamayo@axogeninc.com
| AXOGEN, INC. CONSOLIDATED BALANCE SHEETS (unaudited) December 31, 2023 and 2022 (In Thousands, Except Share and Per Share Amounts) | |||||||
| | December 31, 2023 | December 31, 2022 | |||||
| Assets | | | |||||
| Current assets: | | | |||||
| Cash and cash equivalents | $ | 31,024 | $ | 15,284 | |||
| Restricted cash | 6,002 | 6,251 | |||||
| Investments | — | 33,505 | |||||
| Accounts receivable, net of allowance for doubtful accounts of | 25,147 | 22,186 | |||||
| Inventory | 23,020 | 18,905 | |||||
| Prepaid expenses and other | 2,811 | 1,944 | |||||
| Total current assets | 88,004 | 98,075 | |||||
| Property and equipment, net | 88,730 | 79,294 | |||||
| Operating lease right-of-use assets | 15,562 | 14,369 | |||||
| Intangible assets, net | 4,531 | 3,649 | |||||
| Total assets | $ | 196,827 | $ | 195,387 | |||
| | |||||||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | 28,883 | 22,443 | |||||
| Current maturities of long-term lease obligations | 1,547 | 1,310 | |||||
| Total current liabilities | 30,430 | 23,753 | |||||
| | |||||||
| Long-term debt, net of debt discount and financing fees | 46,603 | 45,712 | |||||
| Long-term lease obligations | 21,142 | 20,405 | |||||
| Debt derivative liabilities | 2,987 | 4,518 | |||||
| Total liabilities | 101,162 | 94,388 | |||||
| | |||||||
| Commitments and contingencies - see Note 14 | |||||||
| | |||||||
| Shareholders’ equity: | |||||||
| Common stock, | 431 | 424 | |||||
| Additional paid-in capital | 376,530 | 360,155 | |||||
| Accumulated deficit | (281,296 | ) | (259,580 | ) | |||
| Total shareholders’ equity | 95,665 | 100,999 | |||||
| Total liabilities and shareholders’ equity | $ | 196,827 | $ | 195,387 | |||
| AXOGEN, INC. CONSOLIDATED STATEMENTS OF OPERATIONS Years ended December 31, 2023 , 2022 and 2021 (In Thousands, Except Share and Per Share Amounts) | |||||||||||
| | 2023 | 2022 | 2021 | ||||||||
| Revenues | $ | 159,012 | $ | 138,584 | $ | 127,358 | |||||
| Cost of goods sold | 31,138 | 24,147 | 22,931 | ||||||||
| Gross profit | 127,874 | 114,437 | 104,427 | ||||||||
| Costs and expenses: | |||||||||||
| Sales and marketing | 86,060 | 80,228 | 73,328 | ||||||||
| Research and development | 28,333 | 27,158 | 24,177 | ||||||||
| General and administrative | 34,943 | 36,758 | 32,338 | ||||||||
| Total costs and expenses | 149,336 | 144,144 | 129,843 | ||||||||
| Loss from operations | (21,462 | ) | (29,707 | ) | (25,416 | ) | |||||
| Other (expense) income: | |||||||||||
| Investment income | 1,487 | 569 | 93 | ||||||||
| Interest expense | (2,835 | ) | (624 | ) | (1,356 | ) | |||||
| Change in fair value of derivatives | 1,531 | 1,044 | (28 | ) | |||||||
| Other expense | (437 | ) | (230 | ) | (278 | ) | |||||
| Total other income (expense), net | (254 | ) | 759 | (1,569 | ) | ||||||
| Net loss | $ | (21,716 | ) | $ | (28,948 | ) | $ | (26,985 | ) | ||
| Weighted average common shares outstanding — basic and diluted | 42,879,000 | 42,083,000 | 41,215,000 | ||||||||
| Loss per common share — basic and diluted | $ | (0.51 | ) | $ | (0.69 | ) | $ | (0.65 | ) | ||
| AXOGEN, Inc. RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES Three Months and Year Ended December 31, 2023 and 2022 (unaudited) (In Thousands, Except Per Share Amounts) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, 2023 | December 31, 2022 | December 31, 2023 | December 31, 2022 | |||||||||||||
| Net loss | $ | (3,893 | ) | $ | (5,415 | ) | $ | (21,716 | ) | $ | (28,948 | ) | ||||
| Depreciation and amortization expense | 1,617 | 713 | 4,491 | 3,093 | ||||||||||||
| Investment income | (336 | ) | (397 | ) | (1,487 | ) | (569 | ) | ||||||||
| Income tax expense | 9 | 125 | 189 | |||||||||||||
| Interest expense | 1,843 | (40 | ) | 2,835 | 624 | |||||||||||
| EBITDA - non GAAP | $ | (760 | ) | $ | (5,014 | ) | $ | (15,538 | ) | $ | (25,611 | ) | ||||
| Non cash stock-based compensation expense | 1,327 | 4,154 | 14,418 | 15,591 | ||||||||||||
| Litigation and related costs | — | 177 | — | 761 | ||||||||||||
| Adjusted EBITDA - non GAAP | $ | 567 | $ | (683 | ) | (1,120 | ) | $ | (9,259 | ) | ||||||
| Net loss | $ | (3,893 | ) | $ | (5,415 | ) | $ | (21,716 | ) | $ | (28,948 | ) | ||||
| Non cash stock-based compensation expense | 1,327 | 4,154 | 14,418 | 15,591 | ||||||||||||
| Litigation and related costs | — | 177 | — | 761 | ||||||||||||
| Adjusted net loss - non GAAP | $ | (2,566 | ) | $ | (1,083 | ) | $ | (7,298 | ) | $ | (12,596 | ) | ||||
| Weighted average common shares outstanding basic and diluted | 43,048,446 | 42,306,012 | 42,878,542 | 42,083,125 | ||||||||||||
| Loss per common share — basic and diluted | $ | (0.09 | ) | $ | (0.13 | ) | $ | (0.51 | ) | $ | (0.69 | ) | ||||
| Non cash stock-based compensation expense | $ | 0.03 | $ | 0.10 | $ | 0.34 | $ | 0.37 | ||||||||
| Litigation and related costs | $ | — | $ | — | $ | — | $ | 0.02 | ||||||||
| Adjusted net loss per common share - basis and diluted - non GAAP | $ | (0.06 | ) | $ | (0.03 | ) | $ | (0.17 | ) | $ | (0.30 | ) | ||||
| AXOGEN, INC. CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY Years ended December 31, 2023, 2022 and 2021 (In Thousands) | ||||||||||||||||||
| | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | ||||||||||||||
| | Shares | Amount | ||||||||||||||||
| Balance, December 31, 2020 | 40,619 | $ | 406 | $ | 326,390 | $ | (203,647 | ) | $ | 123,149 | ||||||||
| | — | |||||||||||||||||
| Stock-based compensation | — | — | 10,919 | — | 10,919 | |||||||||||||
| Issuance of restricted and performance stock units | 254 | 2 | (2 | ) | — | — | ||||||||||||
| Shares surrendered by employees to pay tax withholdings | — | — | — | — | — | |||||||||||||
| Exercise of stock options and employee stock purchase plan | 864 | 9 | 5,458 | — | 5,467 | |||||||||||||
| Net loss | — | — | — | (26,985 | ) | (26,985 | ) | |||||||||||
| Balance, December 31, 2021 | 41,737 | 417 | 342,765 | (230,632 | ) | 112,550 | ||||||||||||
| Stock-based compensation | — | — | 15,591 | — | 15,591 | |||||||||||||
| Issuance of restricted and performance stock units | 343 | 3 | (3 | ) | — | — | ||||||||||||
| Exercise of stock options and employee stock purchase plan | 365 | 4 | 1,802 | — | 1,806 | |||||||||||||
| Net loss | — | — | — | (28,948 | ) | (28,948 | ) | |||||||||||
| | ||||||||||||||||||
| Balance, December 31, 2022 | 42,445 | 424 | 360,155 | (259,580 | ) | 100,999 | ||||||||||||
| | ||||||||||||||||||
| Stock-based compensation | — | — | 14,418 | — | 14,418 | |||||||||||||
| Issuance of restricted and performance stock units | 369 | 4 | (4 | ) | — | — | ||||||||||||
| Exercise of stock options and employee stock purchase plan | 310 | 3 | 1,961 | — | 1,964 | |||||||||||||
| Net loss | — | — | (21,716 | ) | (21,716 | ) | ||||||||||||
| Balance, December 31, 2023 | 43,124 | $ | 431 | $ | 376,530 | $ | (281,296 | ) | $ | 95,665 | ||||||||
| AXOGEN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Years ended December 31, 2023, 2022 and 2021 (In Thousands) | |||||||||||
| | 2023 | 2022 | 2021 | ||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (21,716 | ) | $ | (28,948 | ) | $ | (26,985 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation | 4,218 | 2,827 | 2,744 | ||||||||
| Amortization of right-of-use assets | 1,062 | 1,761 | 1,795 | ||||||||
| Amortization of intangible assets | 273 | 265 | 202 | ||||||||
| Amortization of debt discount and deferred financing fees | 891 | 891 | 831 | ||||||||
| Loss on disposal of equipment | 56 | — | — | ||||||||
| Loss on extinguishment of debt | |||||||||||
| Provision for bad debt | (271 | ) | 612 | (41 | ) | ||||||
| Provision for inventory write-down | 1,939 | 1,769 | 3,314 | ||||||||
| Investment losses (gains) | (666 | ) | (228 | ) | 68 | ||||||
| Change in fair value of derivatives | (1,531 | ) | (1,044 | ) | 28 | ||||||
| Stock-based compensation | 14,418 | 15,591 | 10,919 | ||||||||
| Change in operating assets and liabilities: | |||||||||||
| Accounts receivable | (2,691 | ) | (4,639 | ) | (499 | ) | |||||
| Inventory | (6,054 | ) | (3,656 | ) | (7,478 | ) | |||||
| Prepaid expenses and other | (867 | ) | (84 | ) | 2,435 | ||||||
| Accounts payable and accrued expenses | 6,509 | 660 | (270 | ) | |||||||
| Operating lease obligations | (1,269 | ) | (1,841 | ) | (463 | ) | |||||
| Cash paid for interest portion of finance leases | (3 | ) | (2 | ) | (2 | ) | |||||
| Contract and other liabilities | (14 | ) | — | (3 | ) | ||||||
| Net cash used in operating activities | (5,716 | ) | (16,066 | ) | (13,405 | ) | |||||
| Cash flows from investing activities: | |||||||||||
| Purchase of property and equipment | (13,872 | ) | (20,078 | ) | (27,811 | ) | |||||
| Economic development grant proceeds | — | — | 950 | ||||||||
| Purchase of investments | (10,203 | ) | (39,247 | ) | (68,699 | ) | |||||
| Proceeds from sale of investments | 44,374 | 57,300 | 72,500 | ||||||||
| Cash payments for intangible assets | (1,046 | ) | (1,175 | ) | (589 | ) | |||||
| Net cash provided by (used in) investing activities | 19,253 | (3,200 | ) | (23,649 | ) | ||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from issuance of long-term debt | — | — | 15,000 | ||||||||
| Cash paid for debt portion of finance leases | (10 | ) | (12 | ) | (15 | ) | |||||
| Proceeds from exercise of stock options and ESPP stock purchases | 1,964 | 1,806 | 5,467 | ||||||||
| Net cash provided by financing activities | 1,954 | 1,794 | 20,452 | ||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 15,491 | (17,472 | ) | (16,602 | ) | ||||||
| Cash, cash equivalents, and restricted cash, beginning of period | 21,535 | 39,007 | 55,609 | ||||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 37,026 | $ | 21,535 | $ | 39,007 | |||||
FAQ
What was Axogen's (AXGN) revenue in Q4 2023?
What is Axogen's (AXGN) full-year revenue for 2023?
What was Axogen's (AXGN) net loss in Q4 2023?
What new product is Axogen (AXGN) planning to launch in Q2 2024?
What is Axogen's (AXGN) revenue guidance for 2024?
